This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Is Arbutus Biopharma (ABUS) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Arbutus Biopharma (ABUS) and Annexon, Inc. (ANNX) have performed compared to their sector so far this year.
Is CareCloud (CCLD) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how CareCloud, Inc. (CCLD) and Annexon, Inc. (ANNX) have performed compared to their sector so far this year.
Are Medical Stocks Lagging Annexon (ANNX) This Year?
by Zacks Equity Research
Here is how Annexon, Inc. (ANNX) and CareCloud, Inc. (CCLD) have performed compared to their sector so far this year.
Here's Why Annexon (ANNX) Is a Great 'Buy the Bottom' Stock Now
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for Annexon (ANNX), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Is Annexon (ANNX) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Annexon, Inc. (ANNX) and Avalo Therapeutics, Inc. (AVTX) have performed compared to their sector so far this year.
Annexon (ANNX) Up as Phase III Neuro Disorder Study Meets Goals
by Zacks Equity Research
Annexon (ANNX) jumps 31% after meeting the primary and key secondary endpoints with the low dose of its lead candidate, ANX005, in the phase III study for Guillain-Barre syndrome.
Wall Street Analysts Think Annexon (ANNX) Could Surge 133.72%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at a 133.7% upside potential for Annexon (ANNX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Is Avalo Therapeutics (AVTX) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Avalo Therapeutics, Inc. (AVTX) and Annexon, Inc. (ANNX) have performed compared to their sector so far this year.
Annexon (ANNX) Loses -5.04% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
Annexon (ANNX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Annexon (ANNX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Annexon (ANNX) is expected to provide updates from the phase III study evaluating its lead candidate, ANX005, for the treatment of GBS in the first-quarter earnings release.
Down -43.02% in 4 Weeks, Here's Why You Should You Buy the Dip in Annexon (ANNX)
by Zacks Equity Research
Annexon (ANNX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Are Medical Stocks Lagging Annexon (ANNX) This Year?
by Zacks Equity Research
Here is how Annexon, Inc. (ANNX) and Adma Biologics (ADMA) have performed compared to their sector so far this year.
Annexon, Inc. (ANNX) Falls More Steeply Than Broader Market: What Investors Need to Know
by Zacks Equity Research
In the latest trading session, Annexon, Inc. (ANNX) closed at $6.17, marking a -0.96% move from the previous day.
What Makes Annexon (ANNX) a New Buy Stock
by Zacks Equity Research
Annexon (ANNX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Wall Street Analysts Believe Annexon (ANNX) Could Rally 101.12%: Here's is How to Trade
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 101.1% in Annexon (ANNX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Why Annexon (ANNX) Might Surprise This Earnings Season
by Zacks Equity Research
Annexon (ANNX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Take the Zacks Approach to Beat the Market: Annexon, NVIDIA, Intuit in Focus
by Abhinab Dasgupta
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
Is Annexon (ANNX) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Annexon, Inc. (ANNX) and Novartis (NVS) have performed compared to their sector so far this year.
Annexon (ANNX) Stock Rallies 156% in 3 Months: Here's How
by Zacks Equity Research
Annexon (ANNX) has rallied 156% in the past three months on plans to begin a registrational program for ANX007 in GA after reaching FDA alignment on the study's primary endpoint.
Down -28.96% in 4 Weeks, Here's Why You Should You Buy the Dip in Annexon, Inc. (ANNX)
by Zacks Equity Research
Annexon, Inc. (ANNX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
InflaRx (IFRX) Skyrockets 110% in Six Months: Here's Why
by Zacks Equity Research
Shares of InflaRx (IFRX) show an upward trajectory after it obtained authorization for its first-ever marketed drug, which is approved for the treatment of critically ill COVID-19 patients.
Annexon (ANNX) Stock Down More Than 50% Last Week: Here's Why
by Zacks Equity Research
Annexon (ANNX) announces mixed top-line results from the phase II study of ANX007 in patients with geographic atrophy.
Wall Street Analysts Think Annexon, Inc. (ANNX) Could Surge 241%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 241.4% in Annexon, Inc. (ANNX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
How Much Upside is Left in Annexon, Inc. (ANNX)? Wall Street Analysts Think 246%
by Zacks Equity Research
The mean of analysts' price targets for Annexon, Inc. (ANNX) points to a 246.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Do Options Traders Know Something About Annexon (ANNX) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Annexon (ANNX) stock based on the movements in the options market lately.